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Abstract The head and neck squamous cell carcinoma
microenvironments contain many immune cells and their
secretory products. Many of these cells belong to the mono-
nuclear phagocyte system. The aim of this review is to
study the interactions between mononuclear phagocytes
and head and neck squamous cell carcinoma tissue. The
role of inXammation in tumours and the cytokine interleu-
kin-6 will be highlighted. Future therapy strategies in the
treatment of head and neck cancer might be directed
towards mononuclear phagocytes and their cytokine pro-
duction.
Keywords Mononuclear phagocytes · Innate immune 
system · Macrophages · Monocytes · Interleukin-6 · 
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Abbreviations
VEGF Vascular endothelial growth factor
TGF- Transforming growth factor
GM-CSF Granulocyte–macrophage colony stimulating
factor
TRAIL Tumour necrosis factor-related apoptosis induc-
ing ligand
EGF Epidermal growth factor
PGE2 Prostaglandine E2
Introduction
Head and neck cancer (HNC) is a heterogeneous group of
diseases involving the oral cavity, pharyngeal tube and lar-
ynx. In the United States, where the population is approxi-
mately 300 million, an estimated 40,500 new cases of
HNC arose in 2006, with an estimated mortality of 11.170
persons [1]. Worldwide, 644,000 new cases of HNCs are
estimated to be diagnosed each year, with almost two-
thirds occurring in developing countries [2]. In some of
these countries, HNC can be one of the most common
malignancies. This is mostly due to factors such as poor
oral hygiene, chewing of betel nuts, smoking and drinking
of alcohol [3], but other factors such as genetic susceptibil-
ity and virus infections may play a role in the carcinogene-
sis of HNC [4]. Over 90% of malignancies in the upper
aero-digestive tract are squamous cell carcinomas
(HNSCC) [5].
HNSCC is usually treated with surgery and radiotherapy
either combined or one modality alone. In the past years,
advances in surgical treatment have been mainly made on
the Weld of organ preservation and more eVective means of
reconstruction [6]. Recent advances in radiotherapy include
altered fractionation radiotherapy and radiotherapy com-
bined with chemotherapy for patients with locally advanced
tumours [7, 8]. However, this combined treatment might be
associated with severe side eVects [9]. Many advances in
diagnosis and treatment have been made but the survival
rate for HNSCCC remained stable for the last decade and is
rather low [5]. The highest 5-year survival is for lip cancer,
at 91% but just 31% for hypopharyngeal cancer [5]. There
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survival of HNSCC patients.
Challenges in treatment of HNSCC
Many advances have been made in understanding the carci-
nogenesis and biology of cancer and metastasis. Several
new areas of research have emerged involving biologic
compounds targeting speciWc regions in the cancer cell.
One area of special investigation is the epithelial growth
factor receptor (EGFR) which is expressed in more than
90% of HNSCC tumours and is associated with a poor
prognosis [10]. EGFR inhibitors hold promise in two
important ways: [1] to further improve eYcacy for patients
at risk for recurrence and [2] to decrease treatment-related
toxicities by replacing toxic cytotoxic drugs without jeopar-
dizing survival [11]. Several clinical studies have been per-
formed where monoclonal antibodies, directed against the
extracellular domain of EGFR, are administered, or several
small molecule tyrosine kinase inhibitors are given [12]
These substances are administered combined with radio-
therapy or chemotherapy [13]. Results are promising
despite severe side eVects, but a new standard of treatment
is yet to be found in the clinic [13].
The innate immune system may interact with cancer
cells, both as an inhibitor [14] and facilitator [15] of tumour
growth. This interaction allows using immunomodulating
therapies of cancer by more or less generalized stimulation
of mononuclear phagocytes (MNP). Killed bacterial toxins
[16], along with bacillus Calmette-Guerin (BCG) [17], -
glucan [18], interferons [19] and monoclonal antibodies
[20] are examples of applied biological response modiWers
(BRMs), used as immune stimulators in tumour treatment.
In Japan, it has been a long-standing tradition to use pen-
icillin-killed lyophilized Streptococcus pyogenes, denomi-
nated OK-432 or picibanil, as a BRM in cancer treatment
[21]. Sakamoto et al. [21] published in 2001, a meta-analy-
sis where the beneWts of immunochemotherapy with OK-
432 were assessed in patients with resected non-small-cell
lung cancer. The meta-analysis was based on data from
1,520 patients enrolled in 11 randomized clinical phase III
trials. The 5-year survival rate for all eligible patients in the
11 trials was better with OK-432 treatment, i.e. 51.2% in
the immunochemotherapy group versus 43.7% in the che-
motherapy group. Furthermore, Oba et al. [22] have shown
that patients with resectable gastric carcinoma treated with
adjuvant immunochemotherapy, with OK-432 as one com-
ponent, may improve their survival (performed was a meta-
analysis on 8,009 patients from eight randomized clinical
phase III trials). There are also reports suggesting that
patients with other cancers, such as HNSCC [23], may ben-
eWt from OK-432 treatment. OK-432 may also be used as a
maturation factor for dendritic cells (DCs) as part of vacci-
nation therapy of cancer patients [24]. Despite these con-
vincing results for OK-432 as cancer treatment, OK-432
treatment has not gained any important role as a cancer
drug in Europe or USA. Other new therapies might be
directed towards other target receptors on the cancer cell
such as the Fas receptor [25]. This, as well as other new
(gene) therapies, has not been properly developed, nor have
there been, to our knowledge, performed any clinical studies.
Cancer and the human immune system
The degree of interaction between tumours and the immune
system has been discussed for more than a century. Theo-
ries have been proposed with respect to general tumour
immunology, as well as strategies for immunotherapy in
the treatment of malignant diseases. Ehrlich observed, in
1909, in animal experiments that recipient mice could
acquire immunity to tumour growth. He suggested that the
immune system could detect and respond to cancer cells
because the cancer cell was considered a foreign element
by the organism. Later, this view was further substantiated
and systematized to become the theory we now know as the
“immune surveillance” theory [26]. This theory hypothe-
sizes that malignant cells are exposed to tumour-associated
antigen determinants on their cell surface. These antigens
then induce a T lymphocyte-dependent immune response
that eventually eliminates tumour cells [26]. According to
the theory of immune surveillance, a malignant tumour
may only arise when malignant cells escape an immune
response [27]. There is experimental evidence that malig-
nant tumours can elicit a speciWc T cell-mediated immune
response and suppression of the immune system increases
the incidence of certain types of cancers in humans [28].
Scepticism has been stated towards the general relevance of
immune surveillance in humans [29] and any Wrm role of
immune surveillance in HNSCC patients has yet to be
established [28]. Still, observations from several studies
indicate that immune system-related mechanisms may act
either as stimulatory or inhibitory regulators on the devel-
opment and spread of malignant diseases in humans [30].
Active immune mechanisms protecting the organism
against distant spread of cancer are demonstrated in animal
models [31, 32] and may argue that immune system-related
mechanisms act against tumour cell spread, also in humans.
These immune mechanisms apparently fail to eliminate
tumour cells in progressive cancer disease. This incapabil-
ity of the immune system may be attributed to three princi-
pally distinct reasons [33]:
A. Escape by loss of recognition (loss or alteration of mol-
ecules which are important for the recognition by and
activation of the immune system)123
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mechanisms of cytotoxic lymphocytes)
C. Induction of immune cell dysfunction
When developing eVective strategies for the treatment of
HNSCC, a thorough understanding of tumour cell escape
mechanisms becomes fundamental. Cells of the immune
system may not only fail to act against tumour growth,
but, according to several reports may also support tumour
cell growth. This is, e.g. the case for MNP cells that
secrete growth factors and factors contributing to neo-
angiogenesis by stimulating proliferation and migration
of endothelial cells and local degradation of the extracel-
lular matrix (ECM) [34]. Immune cells should therefore
be regarded as possible “friends or foes” when one
discusses interactions between tumours and the immune
system.
InXammation, cancer and the human immune system
A relationship between cancer and inXammation has since
long been discussed and epidemiological and experimental
evidence points to a connection between chronic inXamma-
tion and development of dysplasia followed by develop-
ment into cancer [35]. InXammation is a very complex
process where many eVector cells and mediators are
involved potentially facilitating tumour growth through
multiple mechanisms [36].
InXammation in tumours
Solid cancers generally show signs of inXammation with
inXux of many types of leukocyte populations. In a deW-
cient immunosurveillance situation, a switch may occur
where cells of the MNP (mainly TAMs) change their phe-
notype from pro-inXammatory to pro-angiogenic, con-
tributing to tumour progression via secretion of
proteases, cytokines and angiogenic factors [34]. Chronic
inXammation can be caused by viruses and contribute to
cellular transformation [37] while bacterial infection may
play a role when an organisms produces free radicals,
such as reactive oxygen and/or nitrogen species, causing
DNA damage and mutations leading to tumour develop-
ment. Chronic inXammation, furthermore, elevates a pop-
ulation of myeloid-derived immunosuppressive cells that
inhibit anti-tumour immunity [38]. IL-1 is a cytokine
that plays a role in this process. In a recent study, mice
deWcient for IL-1 receptor (IL-1R) were inoculated with
mammary cancer cells and compared to non-deWcient
mice. Tumour-associated inXammation as well as tumour
progression was delayed in IL-1R-deWcient mice as well
as number of suppressive myeloid cells. Tumour progres-
sion as well as progression and number of suppressive
cells could be restored by administering IL-6, a pleiotro-
pic cytokine known as a mediator of IL-1, and from that
perspective, a contributing factor in tumourigenesis [36].
For colitis-associated cancer, an animal model has been
developed that reproducibly leads to colonic neoplasia
within the setting of colitis. In this model, a carcinogen is
administered followed by three rounds of chemical colitis
induced by a chemo-irritant in drinking water. After 1–
2 months of treatment, nearly 100% of mice developed
neoplasms in the colon. This model has shown that muco-
sal-derived Nuclear Factor-(NF-)B factor is activated.
NF-B is a pleiotropic transcription factor which plays a
role in both innate and adaptive immunities, and is
required for the expression of several pro-inXammatory
factors [39, 40]. Seen from this perspective, (chronic)
inXammation might be a key factor in cancer develop-
ment. As the head and neck area is prone to exposure to
factors causing irritation and inXammation of the squa-
mous epithelium, it might therefore be plausible that
chronic inXammation also might be a major cause for the
development of HNSCC. It has been shown that NF-B
and its proinXammatory target genes are activated in
HNSCC cell lines and tumour specimens [41]. Blocking
NF-B function in HNSCC greatly reduces tumour
growth and decreases the expression of IL-6 and IL-8
along with many other cytokines and chemokines associ-
ated with the proinXammatory state [42]. As the constitu-
tive activation of NF-B is well established, the
mechanisms of this activation in HNSCC still needs to be
fully elucidated [41].
Adaptive immunity and HNSCC
In HNSCC, stroma is inWltrated with tumour-inWltrating
lymphocytes (TIL).
T-lymphocyte-stimulated proliferation decreases with
increasing tumour burden in HNSCC patients [43]. T-
lymphocyte function, subpopulations in peripheral blood
as well as growth factor responses, may be correlated to
prognosis in HNSCC [44]. A recent publication showed
that total percentage of CD4+ T-cells was signiWcantly
decreased in patients versus controls and that proportion
of Treg cells was signiWcantly elevated in patients relative
to healthy donors. These cells seemed to downregulate
subsets of CD8+ cells, which may play a role in anti-
tumour responses [45]. In a recent study, Aarstad showed
that that a high level of peripheral blood (PB)-derived T-
lymphocyte activation in vivo can predict impaired prog-
nosis with and without adjustment for TNM stage in
HNSCC [46]. The amount of peripheral blood lympho-
cytes might be correlated to tumour load as expressed by
node status.123
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The HNSCC microenvironments also comprise immune
cells and their secretory products. The presence of immune
cells, mainly T lymphocytes and dendritic cells (DC) but
also of B cells, plasma cells, natural killer (NK) cells, mac-
rophages (Ms) and eosinophils, as well as proximity to
cervical lymph nodes, is likely to have an eVect on the initi-
ation, promotion and progression of HNSCC [47]. Cells of
the MNP develop from myeloid progenitors in the bone
marrow and are not only important for innate immunity but
also play a central role in speciWc adapted immunity. In
addition, MNPs participate in several biological processes,
e.g. disposal of dying cells, ingestion of aged erythrocytes,
regulation of inXammatory processes, e.g. tissue repair, ini-
tiating coagulation and stimulation of chemotaxis [48–50].
After maturation and subsequent activation MNPs achieve
varied morphological forms. Monocytes (MOs) may, after
2–3 days in circulation at baseline conditions, move into
diVerent tissues and further diVerentiate into macrophages
(Ms). Ms associated with tumours are called tumour-
associated macrophages (TAMs). MNPs, in general, may
act as defence cells and phagocytes even in the absence of
activation. MNPs are eVective as Antigen presenting cells
(APCs) and are involved in the regulation of immune
responses via interaction with lymphocytes and as eVector
cells in adaptive immune response [51]. The functional
capacity of MNPs depends on the activation level of the
cells.
Ms are relatively large, irregularly shaped cells mea-
suring 25–50 m in diameter. The nucleus is round or kid-
ney-shaped and often eccentrically placed with one or two
nucleoli. Often there is a clearly deWned juxtanuclear Golgi
complex in an abundant cytoplasm [52]. Monocytes (MOs)
are small cells measuring 12–15 m with an eccentrically
placed nucleus which occupies at least 50% of the cell area.
The cytoplasm contains both Wne and large granules as well
as cytoplasmic vacuoles [52].
Phenotypic and functional changes have been described
in MOs from patients with diVerent types of cancer, upon
comparison to controls. In prostate cancer patients, periphe-
ral blood has high levels of phenotypical immature MOs
compared to healthy individuals [53]. Recent data have
demonstrated that myeloid cells accumulating in cancer
patients play an important role in tumour non-responsive-
ness via suppression of antigen-speciWc T cell responses
[54]. On the other hand though, it has been shown that MOs
from cancer patients are activated compared to healthy con-
trols [55, 56], but contact with tumour cells can decrease
function of MOs in cancer [57]. Although some of the
results are conXicting, there is evidence suggesting that
functional activities, as expressed by, e.g. cytokine secre-
tion of MOs in cancer patients, are changed. Changes
observed in systemic responses such as immune responses,
acute phase inXammatory protein responses and decreases
in delayed-type hypersensitivity in HNSCC patients are not
well understood. Still, the local and systemic nature of
these responses suggests that cytokines with pro-inXamma-
tory, pro-angiogenic and immunoregulatory activity pro-
duced by carcinomas could contribute to the pathogenesis
of HNSCC disease. Cytokines that regulate pro-inXamma-
tory and pro-angiogenic responses are detected in tumour
environment as well as systemically in HNSCC patients
[58]. It might not be just tumour-derived factors which con-
tribute to growth and metastasis of the tumour itself. Obser-
vations from several studies have linked certain subsets of
the innate immune system to factors such as clinical prog-
nosis, tumour angiogenesis and invasion [59–62], and it is
now clear that certain subsets of chronically activated
innate immune cells promote growth and/or facilitate sur-
vival of neoplastic cells [63]. In the tumour microenviron-
ment, as well as in circulation, there are diVerent immune
cells that can produce cytokines having these eVects.
Among the cells with most active cytokine secretion are the
MNPs.
HNSCC-derived factors aVecting MNPs
Our laboratory developed an organ culture model
whereby fragment spheroids were established from head
and neck squamous cell carcinoma tissue and autologous
benign squamous tissue. These fragment spheroids
served as vectors for tumour cells in co-cultures with
autologous monocytes. Fragment spheroids developed
within 14 days of in vitro culture whenever adequate tis-
sue was available. Experiments have shown that MCP-1
production by MOs as well as TAM density in HNSCC
tissue was inversely correlated with Erythrocyte Sedi-
mentation Rate level at diagnosis and co-culture [64]. In
other words, presence of “general” inXammation sup-
presses MNP functions, as expressed by MCP-1 produc-
tion. Thus, MNP function in HNSCC patients seems
more to be related to the inXammatory state of the organ-
ism, than previously recognized. We could not deWne a
statistically signiWcant correlation between TNM stage
and TAM density, but there was a trend showing a greater
density of Ms in Malignant F-spheroids from more
advanced TNM staged tumours. Though not statistically
signiWcant, these results correspond to other reports cor-
relating TAM density and function to prognosis in cancer
patients [65] as well as a strong association between M
content, N stage and lymph node metastasis in oral SCC
tumours [66]. A thorough understanding of these mecha-
nisms lends promise to future cancer therapy based on
modulating interactions between tumour cells and the
MNP system.123
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TAMs may play a dual role in the interaction with tumour
cells [67] (Fig. 1). In some situations, a symbiotic relation-
ship may exist between TAMs and tumour cells, thereby
providing support to the tumour in terms of growth and
metastasising capacity. It has, e.g. been shown that a high
amount of TAMs in tumours can be associated with
increased neo-angiogenesis and a worsened survival rate
[68]. TAMs also have the potential for acting cytotoxic
towards tumour cells and some reports state an improve-
ment in prognosis associated with high numbers of TAMs
in tumours [69]. Correlation analyses between number of
TAMs and prognosis in HNSCC have, however, shown that
high levels of TAMs in HNSCC may be related to worse
long-term prognosis [61, 66]. This might be diVerent in
other cancer diseases [30, 68, 70–73]. In recent years, evi-
dence has been provided on Ms being induced by cyto-
kines to polarize into two distinct groups. These two groups
diVer in receptor expression, cytokine and chemokine pro-
duction as well as eVector function [67, 74]. Type I Ms
are eVector cells which kill micro-organisms and tumour
cells and produce anti-inXammatory cytokines while Type
2 Ms regulate inXammatory responses and adaptive Th
immunity, act as scavenger cells, promote angiogenesis, tis-
sue modelling and repair. This deWnition, however, does
not take into account that Ms are not static and that func-
tional and phenotypic changes occur during inXammatory
responses, thereby inducing Ms into an evolving shift in
functional activities and into an unstable, undeWned and
non-functional phenotype [75]. This plasticity of Ms was,
e.g. demonstrated by Watkins et al. [59] in a mouse model.
Functionally polarized TAMs could be converted, from a
tumour-supportive and immunosuppressive phenotype to
an inXammatory functional phenotype, by IL-12 treatment
in vivo as well as in vitro.
Cytokine production and MNPs
Cells of the MNP system secrete many diVerent mediators
of the immune response, such as cytokines and chemo-
kines. When MNPs are activated, genes expressing various
inXammatory mediators are induced, some among these
being cytokine genes. The genes encoding cytokines IL-1,
IL-6, and TNF- are closely regulated and classiWed as
early or immediate genes. These cytokines are denominated
pro-inXammatory [76]. MNPs also secrete peptides, such as
monocyte chemoattractant protein-1 (MCP-1) that have
chemoattractant eVects. Many studies have been done on
functions and clinical relevance of MCP-1, IL-6 and TNF-
. These are highlighted in this review.
Interleukin-6
Interleukin-6 (IL-6) is a 26-kDa protein that is a potent,
pleiotropic, inXammatory cytokine mediating many physio-
logical functions, including developmental diVerentiation of
lymphocytes, cell proliferation and cell survival, as well as
apoptosis. Furthermore, IL-6 has an eVect on bone formation,
general system metabolism, endocrine functions and can
aVect many cells in other tissues and organ systems [77, 78].
The IL-6 receptor (IL-6R) is composed of a ligand-bind-
ing  subunit and a signal-transducing component, desig-
nated gp130. A high production of IL-6, by MOs in cancer
patients with recurrence and/or death from disease, might
Fig. 1 Possible functions of 
TAMs in tumour establishment 
and development. A high accu-
mulation of TAMs in tumours 
can be associated with increased 
neo-angiogenesis but have also 
the potential to act cytotoxic 
against tumour cells by secreting 
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activating Signal Transducer and Activator of Transcrip-
tion-(STAT-)3 in an EGFR-independent matter [79].
STAT3 activation is associated with cell proliferation and
prevention of apoptosis, thereby participating in oncogene-
sis [80], and has been shown to be up-regulated in HNSCC
tissue and in the normal mucosa of the same patient [81].
Recently, IL-6 was shown to have not only an augmenting
inXuence on the invasion potential of HNSCC cell lines but
also an inhibiting eVect on proliferation rate [82, 83].
Monocyte chemoattractant protein-1 (MCP-1)
Chemokines, a family of low-molecular-weight cytokines
that play key roles in immune response and in development
of several cell types, are classiWed mainly into CC and
CXC subfamilies according to location of the Wrst two cys-
teine residues. MCP-1 (or CCL2) was originally thought to
be a selective chemokine for MOs, but later been shown to
also have eVects on T lymphocytes [84], NK cells [85] and
basophilic granulocytes [86, 87]. MCP-1 is structurally and
genetically related to other chemokines (MCP-1, -2, -3, and
-4 in humans, MCP-1, -2, -3, and -5 in the mouse) with sim-
ilar properties. They all activate the same receptor, CCR2,
with similar potencies [88]. Many studies have been per-
formed relating synthesis of MCP-1 and inXux of TAMs in
tumour tissue and relating this inXux to factors, such as
angiogenesis, invasion and prognosis [61, 62, 70]. Lately,
evidence has been provided on MCP-1 possibly being
responsible for recruitment of myeloid suppressor cells into
tumour. As such, having a pro-tumour eVect in itself [89].
Various types of cancer cells, including ovarian, breast and
colorectal cancer cells, synthesize and express chemokine
receptors [90].
Tumour Necrosis Factor- (TNF-)
Tumour Necrosis Factor-(TNF-) is a polypeptide of 157
amino acids and in humans. It is expressed on the cell
membrane of a majority of cells, with the exception of
erythrocytes and resting T lymphocytes [91]. TNF- is a
pleiotropic cytokine and plays an important role in the path-
ophysiology of diVerent diseases, such as sepsis and rheu-
matoid arthritis. Blocking TNF- production is very
eVective in reducing local and systemic inXammation in
patients with rheumatoid arthritis and psoriasis [92]. TNF-
promotes killing of tumour cells through apoptosis via
binding with death-domains in tumour cells, stimulating
NK cells and activating CD8+ cells [93].
TNF- molecules are membrane-bound or circulate in
two forms, either as biological active molecules or as
immunologically detectable but inactive peptides. There are
inhibitory mechanisms that protect cells from TNF-
activity, such as circulating TNF receptors and membrane-
bound “decoy” receptors [93].
Transcripts of protooncogenes (c-jun and c-fos), tran-
scription proteins, such as the immediate-early growth-
response transcription factor Egr-1 as well as subunits of
NF-B family p50 and p65, are involved in induction of
TNF- gene transcription by binding to speciWc sites on the
TNF- promoter region [94].
Monocyte IL-6 production as a prognostic factor
Our research showed that IL-6 secretion by LPS-stimulated
MOs from HNSCC patients predicted prognosis [95]. Fur-
thermore, we found a correlation as to the amount of IL-6
produced in co-culture of MOs with F-spheroids and recur-
rence of disease, as well as prognosis of patients [96]. For
MCP-1 though, we could not Wnd any major correlation as
to recurrence and prognosis. This general, predictive, value
of IL-6 secretion from MOs stimulated with diVerent stim-
uli, such as LPS and co-culture, is interesting as well as
intriguing. In LPS-stimulated MO cultures the main source
of IL-6 is the MO as low levels of IL-6 in serum minimally
contribute to the total amount. In a recent longitudinal and
prospective cohort study DuVy et al. [97] were able to show
that pre-treatment serum IL-6 levels predicted survival and
recurrence in HNSCC patients. Still, changes in cytokine
levels in serum may have input on the regulatory eVects of
MO when stimulated under in vitro and autologous condi-
tions. We observed no diVerence between autologous and
serum-free culture conditions in terms of the predictive role
of MO-derived IL-6 secretion.
It seems that increased MO responsiveness, as measured
by IL-6 secretion, is a negative prognostic factor both with
LPS and in co-culture with F-spheroids.
MOs in HNSCC patients might be functionally changed
due to several factors related to presence of malignant dis-
ease. Cytokines and growth factors, produced in or around
the vicinity of the tumour, could not only aVect the immune
system locally but also generally, i.e. by aVecting mono-
blast development in the bone marrow. Such an MO-prim-
ing eVect seems to be more qualitative than quantitative, i.e.
non-linear to the tumour burden [96]. These Wndings
strongly indicate that MOs in HNSCC patients are func-
tionally changed as a consequence of disease and the inXu-
ence of other factors, such as level of tumour burden and
inXammation, are secondary to this eVect. We actually
found that IL-6 production from MOs in co-culture with
benign fragment spheroids has prognostic value as to loco-
regional recurrence and survival. Our hypothesis is that this
might be a display of Weld cancerization whereby changed
dysplastic epithelia is found throughout mucosa of both the
upper and lower respiratory tracts, as well as to some extent
in the oesophagus, which in turn may give rise to cancer at123
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BF-spheroids could be linked with dysplastic-transformed
epithelia, which stimulates MOs, as shown by an elevated
BF-spheroid co-culture response in patients who perished
(from cancer disease) during follow-up. Alternatively, it
may be a characteristic of MOs that is associated with prog-
nosis under BF-co-culture condition. Such an explanation is
in line with published studies both as to serum values of
pro-inXammatory cytokines [99] and secretion of pro-
inXammatory cytokines by immune cells [100].
InXammation and cytokine production
It cannot be determined whether this observation is related
to the eVect of IL-6 per se or the increased IL-6 MO respon-
siveness, as a result of increased inXammatory response in
diseased patients. A changed inXammatory state may be
present in HNSCC patients, as shown by, e.g. increased
ESR and lowered albumin values in serum [101]. Still, a
pro-inXammatory cytokine, such as IL-6, could possibly
enhance the inXammatory response towards the tumour in a
way that could enhance tumour aggressiveness. IL-6 may
activate NF-kB, a nuclear regulator in the expression of
multiple genes in cells, thereby making a possible link
between infection, inXammation and carcinogens to cancer
development [40]. The observed signiWcantly higher pro-
duction of IL-6 by MOs in patients with recurrence and/or
death from disease [96] might also be linked to an IL-6/gly-
coprotein130 stimulation, which activates STAT3 in an
EGFR-independent manner [79]. STAT3 activation is asso-
ciated with cell proliferation and prevention of apoptosis,
thereby participating in oncogenesis [80] and has been
shown to be up-regulated in HNSCC tissue and in the
benign mucosa of the same patient [81].
Future perspectives
Several strategies might be feasible as to immunotherapy,
e.g., cancer vaccine-based immunotherapy should enhance
immunosurveillance and prevent and protect against grow-
ing tumours [102]. Trials have been done with tumour-
associated antigens (TAA) and peptides though objective
clinical responses are still rare [103]. Studies have been
performed where MNPs have been used as an adjuvant tool
in treatment of HNSCC [104, 105]. Many of these studies
are Phase I and II studies particularly using DCs as an adju-
vant to surgery, radiotherapy and chemotherapy [105].
Other clinical studies have also focused on the use of NK
cells as a form of immunotherapy where endogenous NK
cells are activated by infusions of cytokines, or allogeneic
cells are adoptively transferred to a donor with cancer
[106]. Unfortunately though, no reports have yet been pub-
lished validating the use of this kind of immunotherapies as
adjuvant therapy.
TAM in tumours might promote a type II stage induced
in part by tumour hypoxia. In this way, TAM promotes
tumour growth by inducing neo-angiogenesis. In this view,
strategies could be developed to prevent TAMs from diVer-
entiating into a type 2 phenotype, thereby inhibiting neo-
angiogenesis. On the other hand, TAMs might be used as a
vehicle for delivering anti-tumour “substances” to speciWc
areas prone to hypoxia where agents, such as chemothera-
peutical drugs, are less potent due to lack of blood vessels.
One might also inhibit the function of TAMs themselves,
e.g. cytokine secretion. IL-6 might be one of the cytokines
that might be targeted in the treatment of cancer in general.
Monoclonal recombinant antibodies against circulating IL-
6 and the IL-6 receptor (IL-6R) have been successfully
applied in the treatment of juvenile rheumatoid arthritis and
Castleman disease [107]. Other strategies might be directed
towards the IL-6/gp130 autocrine/paracrine mechanism
that activates STAT3. Several substances are known to
inhibit IL-6-induced activation of STAT3 [107], most nota-
bly steroids which are potent inhibitors of IL-6 production.
As interactions between MNPs and HNSCC are not
completely disclosed, one might ponder on how the
enhanced IL-6 production of MOs in HNSCC patients can
be used in a clinical setting. Many cells produce IL-6 and as
such it is important to determine the nature of the main
Table 1 Possible strategies feasible as to immunotherapy in head and neck squamous cell carcinoma
Strategy Method Goal References
Cancer vaccine based Tumour associated antigens Enhancement of tumour surveillance [102, 103]
Dendritic cells Arrest of tumour development 
and growth
[104]
Natural killer cells [68]
Modulation of function 
of tumour associated 
macrophages
Inhibiting type II diVerentiation of TAM Inhibiting neo-angiogenesis [49, 64]
TAM as a vehicle for chemotherapeutical substances 
in hypoxic areas in tumour tissue
Intra-tumoural therapy [64]
Inhibition of TAM cytokine secretion Monoclonal antibodies against 
circulating IL-6 and IL-6R
[105]
STAT3 activation Steroids, PS-341, Ecosapentaenoic acid, Atiprimod Inhibition STAT3 activation [105]123
342 Eur Arch Otorhinolaryngol (2010) 267:335–344stimulus responsible for this raised IL-6 production by
MNPs. This is an interesting and important line of explora-
tion for future studies (Table 1).
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